Table 4 Variables associated with overall survival among 284 patients

From: Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study

Co-variable	No.	Univariate analysis		Multivariate analysis
		MST (months)	P	Variate	OR	95% CI	P
Age
< 70	231	22.8
> 70	53	24.3	0.625
Gender
Male	168	20.1
Female	116	32.4	0.0086	Female	1.06	0.75-1.58	0.75
Smoking status
Yes	174	20.1
No	110	33.4	0.0012	No smoking status	0.84	0.52-1.24	0.39
ECOG PS
0-1	238	29.5
>2	46	7.9	<.0001	PS 0-1	0.34	0.24-0.50	<.0001
Stage
IIIB	25	30.2
IV	259	22.5	0.269
EGFR mutation
Mt (+)	121	39.2
Mt (−)	163	17.8	<.0001	Mutant EGFR	0.53	0.34-0.84	0.0069
PCV
< 2.2 ng/ml	150	38.6
≥ 2.2 ng/ml	134	15.0	<.0001	< 2.2 ng/ml	0.43	0.31-0.59	<.0001
CEA
< 5.0 ng/ml	108	32.6
≥ 5.0 ng/ml	176	21.0	0.036	< 5.0 ng/ml	0.93	0.67-1.26	0.63
Start dates of IT
Before 1/ 4/ 2008	79	34.1		After 1/ 4/ 2008
After 1/ 4/ 2008	205	19.3	0.0030		0.73	0.50-1.15	0.07
EGFR-TKI treatment
Yes	143	33.7
No	141	15.3	<.0001	Yes	0.76	0.50-1.15	0.20

IT: initial therapy, PCV: pretreatment CYFRA 21–1 value, Mt(+): mutant EGFR, M(−): wild-type EGFR.

Back to article page